About the Remunity® Pump for Remodulin® Developed in conjunction with DEKA Research and Development Corporation, Remunity is a discreet, subcutaneous delivery system designed for adults (age 22 ...

EVER Pharma Launches Innovative, Patient Friendly Subcutaneous Pump for Parkinson´s Disease EVER Pharma Infusion Pump (Graphic: Business Wire) July 01, 2019 02:00 AM Eastern Daylight Time ...

Remunity Pump is intended for continuous subcutaneous delivery of Remodulin, a prostacyclin vasodilator, in prefilled cassettes for the treatment of PAH in adults aged 22 years and older.

UC study: Subcutaneous infusion pump safe, effective for Parkinson’s treatment Results of phase 3 trial published in the Lancet Neurology Peer-Reviewed Publication University of Cincinnati ...

Liquidia (LQDA) and Sandoz will collaborate with Mainbridge Health Partners to develop a new infusion pump Liquidia and Sandoz have also extended the term of their promotion agreement for ...

ITCA650 Subcutaneous Pump ITCA650 is a unique formulation of exenatide currently in development, which delivers medication through an implantable subcutaneous pump delivery system. The osmotic ...

The FDA didn’t raise any questions about ABBV-951’s efficacy or safety, but it requested additional information about the combo’s subcutaneous pump device, AbbVie said.

Label expansion of Tyvaso to cover patients in PH WHO Group 3, launch of RemUnity subcutaneous pump, and progress of Ralinepag through clinical trials are highlights to look out for.

Three of these deaths involved outpatient use of terbutaline given by subcutaneous pump, and 9 involved use of oral terbutaline alone or in addition to subcutaneous or intravenous terbutaline.

About the Remunity ® Pump for Remodulin ® Developed in conjunction with DEKA Research and Development Corporation, Remunity is a discreet, subcutaneous delivery system designed for adults (age ...

In connection with the execution of the Pump Agreement, Liquidia and Sandoz also agreed to extend their promotion agreement for Treprostinil Injection by another five years until December 31, 2032.